p e r s p e c t i v e
In vitro display technologies, best exemplified by phage and yeast display, were first described for the selection of antibodies some 20 years ago. Since then, many antibodies have been selected and improved upon using these methods. Although it is not widely recognized, many of the antibodies derived using in vitro display methods have properties that would be extremely difficult, if not impossible, to obtain by immunizing animals. The first antibodies derived using in vitro display methods are now in the clinic, with many more waiting in the wings. Unlike immunization, in vitro display permits the use of defined selection conditions and provides immediate availability of the sequence encoding the antibody. The amenability of in vitro display to high-throughput applications broadens the prospects for their wider use in basic and applied research.
For the past 35 years, hybridoma technology has enhanced our capacity for research and diagnostics by providing monoclonal antibody reagents to track, detect and quantify target molecules in cells and serum. Recently, several more advanced methods to harness the immune response [1] [2] [3] have substantially increased the number of antibody-producing cells that can be screened. In addition to these improvements in more traditional methods of making monoclonal antibodies, researchers can also benefit from refinements in in vitro display technologies. Although their merits do not seem to be fully appreciated across the broader research community, display technologies permit more control over the nature of the derived antibodies than immunization. Since the conception 4 and first implementation 5 of phage display, perhaps the most notable landmarks in the evolution of display technologies have been the expression of antibody fragments in bacteria 6 and PCR-mediated amplification of antibody genes and libraries [7] [8] [9] [10] [11] . The most popular technologies, phage 8, 12, 13 and yeast display 14, 15 , which are complementary in their properties, can be used with naive, immunized or synthetic repertoires.
The advent of high-throughput biology has dramatically increased the demand for renewable, high-quality affinity reagents for use in proteome-scale experiments. Whereas further advances in animal immunization technologies are expected to be slim, in vitro methods have the potential to substantially improve the parallelization, automation and miniaturization of antibody screens. Furthermore, a raft of recent papers [16] [17] [18] [19] [20] [21] [22] point to an alarmingly high proportion of commercial antibodies demonstrating poor specificity, or even failing to recognize their targets at all. Given that much of modern biological research relies on the fidelity of commercially supplied antibodies, this underscores the importance of robust approaches to improve antibody quality. The high-throughput potential of in vitro technologies make them ideal platforms for large-scale projects to derive antibodies for all human proteins. Once completed, these initiatives are likely to have impacts that potentially rival the completion of the human genome.
Our primary goal here is not to reiterate the ways in which libraries used in display technologies are made or used. Instead, we discuss the scope of in vitro display technologies and what they have enabled, in particular in the context of distinguishing subtle differences in protein sequences and conformations or even minor changes in the chemical structures of small molecules. We hope to illustrate how in vitro display methods have yielded antibodies with remarkable properties, some of which have never been obtained by immunization. Most of the examples we discuss relate to antibody fragments. However, display technologies have allowed the development of nonantibody scaffolds. These also provide affinity reagents with similar, or in some applications, superior properties to those described here. Selection platforms [23] [24] [25] and different scaffold proteins [26] [27] [28] , including antibody fragments 29 , have been reviewed elsewhere.
Unique features of display technologies
By permitting control over selection and screening conditions, display technologies allow the generation of antibodies against defined antigen conformations or epitopes ( Fig. 1) . For instance, the inclusion of competitors can direct selection toward specific targets. The use of variable regions from immunized sources with display technologies can also enable selection of specificities not detectable by traditional immunological techniques 30 . Because the gene encoding the antibody is cloned at the same time as the antibody is selected, simple subcloning steps after in vitro display permit the creation of constructs with added functionalities (Fig. 1) . Libraries of mutagenized variants can be created and the same selection process repeated to yield variants with superior specificity and affinity. The improvement of antibody affinity to picomolar levels [31] [32] [33] [34] [35] has become relatively routine, with one study describing an antibody in the femtomolar range 36 . These affinities are far higher than those of antibodies obtained by immunization, which are limited to ~100 pM by the physiological mechanism of B-cell activation 37, 38 . In addition, antibody specificities can be broadened or narrowed by appropriate selection and screening. p e r s p e c t i v e As these in vitro methods are based on microbial systems, selection and screening are more amenable to automation than earlier hybridoma-based approaches. This provides the potential for highthroughput generation of binders 39, 40 . In vitro methods also overcome immunological tolerance, allowing the selection of affinity reagents that recognize highly conserved targets such as ubiquitin 41 , histones 42 , hemoglobins 43 and post-translational modifications [44] [45] [46] . Several approaches are available for overcoming tolerance during immunization 47, 48 . However, none is required to select antibodies against conserved proteins using in vitro display methods. Remarkably, the selection of hundreds of different antibodies from naive human antibody repertoires against many different individual human targets has not been problematic 39, 49, 50 .
Recognition of chemical modifications and small molecules
A single methyl or hydroxyl group can have a considerable effect on the biological properties of a steroid hormone. Similarly, protein phosphorylation, acetylation and sulfation, all of which are relatively simple post-translational modifications in chemical terms, can dramatically affect signal transduction. Binders capable of discerning such relatively simple chemical modifications are of great value in studying these effects. Monoclonal and polyclonal antibodies with specificities for small molecules have been obtained by traditional immunization [51] [52] [53] [54] [55] . Even so, the ability of display methods to tailor both affinity and specificity has generated antibodies capable of discerning minor differences between related small molecules far better than those obtained by immunization ( Table 1 and Fig. 2) .
Although space constraints do not permit discussion of all of these studies, the use of phage display to study tyrosine sulfation warrants particular mention. The sulfation of tyrosine residues is a post-translational modification predicted to occur in 30% of all secretory and membrane proteins 56 . Despite decades of efforts involving immunization, it has proved impossible to generate antibodies recognizing sulfotyrosine using traditional means. This probably results from the innate tolerance of immune systems for such ubiquitous protein modifications, as well as the presence of the recognized target in the secretory pathway, resulting in retention and an inability to secrete the antibody. Using phage display, two groups recently selected antibodies recognizing proteins containing sulfotyrosine (but not tyrosine phosphate), independently of protein context or sequence 45, 46 . These antibodies recognized sulfotyrosinated proteins in western blot analysis, immunofluorescence, enzyme-linked immunosorbent assays (ELISA) and immunoprecipitation, and recognition could be abolished by sulfatase treatment or preincubation with free tyrosine sulfate. This represents an enormous advance in the analysis of this modification, which has traditionally required thin-layer chromatography of radiolabeled protein hydrolysates 57 or mass spectrometry 58 , with the presence of sulfate groups often inferred, rather than proven. The ability to select antibodies with such subtle recognition properties is likely to be a boon in the development of novel materials, in which antibodies could be used to facilitate and detect chemical patterning.
Recognition of subtle differences in proteins
In vitro display technologies allow the generation of antibodies against almost any target, including toxins, pathogens and antigens that are neither immunogenic nor highly conserved. With respect to protein targets, the exquisite specificity of the antibodies selected is exemplified by binders capable of differentiating, for example, as shown (see A.B. and collaborators 59 ), between chicken and quail lysozyme (which differ by a single surface amino acid) and the SH2 domains of ABL1 and ABL2 (refs. 60,61 and Table 2 (which have 89% sequence similarity)) Phage antibody libraries have been widely used to select antibodies against infectious agents. These include antibodies that discriminate between different strains of hantavirus 62 , dengue virus 63 , influenza 64, 65 , Ebola 66 and Venezuelan equine encephalitis virus 67 . Given that many of these viruses are classified serologically, the ability to select phage antibodies with similar specificities is not surprising. Nonetheless, unlike antibodies generated by immunization, these have the potential to be used therapeutically. Human antibodies, some of which are protective in animal models [68] [69] [70] , have also been selected against a number of bacterial biothreat targets, including Brucella melitensis 71 , Burkholderia mallei and Burkholderia pseudomallei 72 , anthrax toxins 68,73,74 and spores 75 , and botulinum toxin 31, 76 . Figure 1 The unique capabilities of in vitro selection offer advantages over the immunization of animals for antibody generation. The direct coupling of the antibody and its encoding gene is characteristic of all display methodologies, including phage, yeast and ribosome display. Defined panning conditions with the desired buffer conditions, cofactors and competitors ensure that libraries can be screened using antigens with the desired conformation and biochemical properties to select for the requisite level of binder specificity and affinity. Binders can be selected sequentially, using different antigens to identify shared epitopes. The immediate availability of the antibody gene provides much additional value relative to antibodies obtained by immunizing animals. p e r s p e c t i v e One library 70 was generated from military donors vaccinated against a plethora of different biothreat agents, reflecting the additional ability of display technologies to exploit antibodies generated during traditional immunization.
The in vitro nature of phage display technology has been exploited to target particular features of blood cells. In one study 43 , antibodies recognizing fetal hemoglobin, but not adult hemoglobin, were selected by depleting high-affinity, cross-reactive antibodies followed by a selection against the fetal protein. Notably, the selected discriminatory antibody was of much lower affinity than cross-reactive antibodies, demonstrating the power of negative selections to favor clones with desirable binding specificities, even if their affinity is lower. Similar methods applied to cells have been used to select antibodies specifically recognizing fetal nucleated red blood cells 77 .
Protein allostery is a common means for the regulation of protein function, and many signaling proteins exist in alternative conformational states that mediate different cellular responses. Antibodies that recognize specific protein conformers are powerful tools for probing the details of cell signaling ( Table 2) . However, the generation of such antibodies by immunization is complicated by the difficulty of maintaining a particular protein conformation in an immunized animal. Two ways in which in vitro selection technologies can address these limitations involve the use of negative selections to deplete nonspecific binders as well as those binders recognizing the nondesired protein conformation, and then following these with affinity maturation strategies to fine-tune specificity. In one study, single-chain Fvs (scFvs) specific to the GTP-bound form of the small GTPase Rab6 were generated by performing selections against a GTP-locked mutant 78 . In another study, one of our groups (S.S. and collaborators 79 ) used small molecules to covalently lock caspase-1 in either the active or inactive form and the locked antigens were used to select Fabs that were highly selective for either the 'on' or 'off ' form of the protease. The concept of using in vitro selections to generate conformationspecific antibodies has also been combined with selections on whole cells in a powerful strategy that enables the probing of cell surfaces for conformational changes in response to various stimuli 80 .
Phage display has also generated antibodies able to recognize structured RNA molecules 81 , which are essentially nonimmunogenic, and not amenable to detection using simple nucleotide probes ( Table 2) . By ensuring a nuclease-free in vitro environment and selecting under conditions optimized for the structural stability of the RNA, high-affinity Fabs were isolated against a structured domain from the Tetrahymena group I intron. These results establish general methods applicable to the generation of antibodies against other structured RNAs and may be useful to decipher the biological roles of the vast numbers of noncoding RNAs found in metazoan transcriptomes.
Recognition of cell surface receptors
Communication between cells is largely controlled by interactions between cell surface receptors and the ligands they recognize. Figure 2 In vitro selected antibodies can recognize minute differences in small molecules. (a) Antibodies against 6-monoacetylmorphine, the major heroin metabolite, do not recognize the closely related morphine 154 .
(b) Many different antibodies have been selected and subsequently had both affinity and specificity matured to specifically recognize 17β-estradiol, testosterone and progesterone without cross-reacting with closely related steroids ( Table 1) . (c) Antibodies against proteins bearing sulfated tyrosine residues do not recognize proteins containing either tyrosine or tyrosine phosphate 45, 46 . Chicken versus quail lysozyme Differ by only four amino acids, of which only one is surface exposed 59 MHC, major histocompatibility complex. p e r s p e c t i v e
Antibodies can modify such interactions and many therapeutic antibodies exert their effects by interfering in communications at the cell surface using different mechanisms ( Fig. 3 and Table 3 ). In vitro display technologies provide a powerful route to generating functional antibodies that interfere with normal or pathological extracellular signaling. Although it is usually difficult to select for function directly, display technologies have the ability to generate thousands of independent binders, each of which can then be screened for functional activity. For example, >1,200 different antibodies directed toward B-lymphocyte stimulator (BLyS) were generated by phage display 82 . This large panel was subsequently screened using biochemical and cellular assays to identify antibodies that bound to BLyS, preventing its interaction with the receptor (Fig. 3a) and thereby blocking B-cell activation. In some cases, blocking antibodies with subnanomolar affinities were isolated directly from the naive antibody-phage display library 82 . One of these antibodies, specific only for the secreted form of BLyS (Benlysta), was affinity matured 83 and is close to approval for treatment of systemic lupus erythematosus. Similar results have been reported for the selection of phage antibodies against a panel of 28 different, potentially therapeutic targets, with an average of 120 functionally active (that is, antagonistic or agonistic) antibodies selected per target 50 .
An alternative strategy to block receptor signaling is to target the ligand-binding sites on the receptors, thereby blocking access to the natural ligand (Fig. 3b) . This was used to select antibodies that prevent the interaction of insulin-like growth factor type 1 (IGF-1) with the IGF-1 receptor 84 . Several groups of receptor binders were generated that competed with ligand binding and blocked cell growth in vitro and in vivo. These antibodies were also found to reduce receptor expression by internalization and catabolism.
Studies on a panel of therapeutic antibodies targeting the epidermal growth factor (EGF) receptor (ErbB1) have also shown competition with ligand binding. However, antibodies can also block receptor signaling by alternative mechanisms 85 . The four extracellular domains of ErbB1 adopt a mainly closed conformation in the absence of ligand, and a more extended conformation (allowing dimerization and subsequent phosphorylation of the intracellular domain) in the presence of ligand. Structural studies have shown that whereas antibodies such as zalutumumab keep intracellular domains apart, preventing phosphorylation ( Fig. 3c) , cetuximab (Erbitux) stabilizes the receptor in the closed conformation ( Fig. 3d) . Among the anti-ErbB2 antibodies, pertuzumab (Omnitarg) appears to work by preventing dimerization (Fig 3c) , whereas trastuzumab (Herceptin) prevents receptor shedding and p e r s p e c t i v e forms inactive tetramers 85 . Although the original blocking antibodies in these examples were generated from mice, they demonstrate the therapeutic approaches that could benefit from human antibodies isolated directly from display technologies. Antibodies that block Notch signaling reveal yet another mechanism of action. Following ligand binding, a conformational change occurs at the juxtamembrane negative regulatory region. This exposes a protease cleavage site, resulting in the release and translocation to the nucleus of the intracellular domain. In addition to generating antibodies that block the interaction with ligand, antibodies recognizing the negative regulatory region domains stabilized the 'closed' confirmation of the Notch receptor ( Fig. 3d) , preventing the proteolytic cleavage and translocation of the intracellular domain 86, 87 .
Dimeric antibodies targeting ligand-binding domains sometimes mimic the natural ligand, causing receptor activation rather than inhibition. This is the case for antibodies recognizing c-Met 88 , with monomeric antibodies being antagonistic. Even so, in the case of tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1) and receptor 2 (TRAIL-R2) (ref. 89) , an analysis of >500 distinct selected antibodies revealed some that were agonistic even as monomeric scFvs or Fabs. This is difficult to reconcile with the mode of action of TRAIL, which is a homotrimeric ligand that causes multimerization of TRAIL receptors, leading to apoptosis particularly in tumor cells overexpressing the receptor.
Antibodies also have great potential in blocking protein interactions associated with viral entry into target cells, illustrated by antibodies selected from naive antibody libraries against recombinant hemagglutinin 5 (H5) influenza ectodomain 90, 91 . Structural analysis of one of the antibodies showed that it bound to hemagglutinin at a highly conserved, previously unrecognized pocket found in many different influenza viruses. Binding prevents the structural reorganization required for membrane fusion, rendering the antibody neutralizing. Although antibodies have not been generated against this epitope by traditional immunization or infection, antibodies with similar V H gene usage and neutralizing activity have been selected from phage antibody libraries created from recently infected individuals 30 , showing that phage display can access the diversity of immune responses in ways not possible by traditional immunological means.
In vitro selection schemes have also been devised that allow the direct selection of antibodies mediating internalization 92 . This was carried out by incubating phage libraries with target cells and isolating those phage antibodies found within the cell after removing phage antibodies bound to the cell surface. The recognized antigen is usually identified after selection. However, the use of mammalian cells transfected with the target of interest 93 , or yeast displaying targets of interest on their surface 94 , provides a means of carrying this out on predetermined targets. This approach is particularly suitable for the selection of antibodies used for specific targeting of chemotherapeutics 95, 96 .
In summary, antibodies and other binding molecules provide a means of modulating biological function by specifically interfering in protein interactions. In vitro display systems provide a means of presenting targets in appropriate conformations, including on cell surfaces. This facilitates rapid screening for potentially rare functional binders.
Improving antibody affinity and specificity
Although initial leads can be used directly as affinity reagents, a major advantage of in vitro methods is that it is possible to further improve function by constructing secondary libraries that introduce additional mutations. Secondary libraries are most commonly used to improve affinity, and all three major display formats (phage, yeast and ribosome) have been applied to develop affinities that exceed those possible with natural antibodies ( Table 4 ). Both stepwise 97 and computational 98 methods generate similarly high-affinity antibodies, but they have not been used as widely as in vitro display methods. There are many examples of in vitro affinity maturation, and here we highlight some key studies. In ribosome display, each selection cycle involves a PCR-amplification step, which is ideal for introducing additional mutations by error-prone PCR. This strategy has been used to simultaneously select and affinity-mature anti-insulin antibodies with affinities in the subnanomolar range 33 . Yeast-displayed libraries are smaller than phage and ribosome libraries, yet they allow quantitative and exhaustive screening by fluorescence-activated cell sorting. Coupled with sequential rounds of error-prone PCR, modest libraries of 10 5 -10 7 unique clones were sufficient to affinity-mature an anti-fluorescein scFv to affinities <100 fM 36 .
Antibody engineering efforts usually strive to obtain specificity for an antigen of interest. However, in certain applications, defined cross-reactivity is extremely useful. Species cross-reactivity allows better assessment of therapeutic efficacy and toxicity in animal models. Unfortunately, cross-reactive antibodies are often difficult to obtain by hybridoma methods owing to tolerance. In contrast, in vitro libraries are unaffected by immune tolerance and antibodies targeting conserved sites across species have proven to be more the rule than the exception. For highly conserved proteins, such as vascular endothelial growth factor (VEGF), human/mouse cross-reactive antibodies have been obtained directly from naive libraries 99, 100 . In the case of less conserved orthologs, such as BAFF/BLyS receptor 3 (BR3), initial anti-human antibodies with weak cross-reactivity to the mouse protein have been obtained from naive libraries and evolved to be highly cross-reactive 101 . Similar approaches have been used to generate antibodies recognizing two closely related chemokines (C-X-C motif ligand 10 and C-X-C motif 9) 102 , thereby permitting neutralization of two human chemokines with a single antibody.
Most attempts to engineer specificity involve improving on preexisting weak recognition, due to homology between the recognized targets. In perhaps the most extreme case of engineered crossreactivity, trastuzumab has been evolved to recognize a very different Modification of recognition specificities CXCL10 and CXCL9 Antibody selected against CXCL10 and evolved to also recognize CXCL9
VEGF and ErbB2
Antigens are completely unrelated, and antibody binds with 3 nM and 0.2 nM affinity to VEGF and ErbB2, respectively p e r s p e c t i v e protein, vascular endothelial growth factor (VEGF), as well as its original target, ErbB2 (ref. 103) . After considerable evolution, the affinities for both targets were comparable to those of therapeutic antibodies (K d = 3/0.2 nM for VEGF/ErbB2). The antibody inhibited both VEGF and ErbB2-mediated cell proliferation in vitro and tumor progression in mouse models. The structures of the bispecific Fab in complex with ErbB2 or VEGF revealed a common paratope, with the ErbB2 functional paratope located predominantly on V H , and that for VEGF on V L (Fig. 4) . The ability to design antigen-binding sites with dual specificity against structurally unrelated antigens may be important in therapeutic strategies targeting two distinct signaling pathways with a single antibody. The ability to improve affinity and broaden specificity also has major implications for the development of antibodies against pathogens. For the effective inhibition of viral infection and bacterial toxins, antibodies would ideally recognize a variety of antigen subtypes with high affinity, to afford broad protection against pathogen variants. Furthermore, several studies have shown that multiple antibodies targeting distinct epitopes provide synergistic effects necessary for effective neutralization of pathogens 104, 105 . In vitro antibody technologies provide an effective means for achieving these demanding criteria, as exemplified by a long-term study of neutralizing antibodies against the botulinum neurotoxin. Phage antibody libraries from immunized mice and humans resulted in the isolation of three antibodies recognizing nonoverlapping epitopes on botulinum neurotoxin 106 . The use of these three antibodies together as an oligoclonal IgG provided strong synergy that dramatically increased toxin neutralization. A long series of affinity and specificity maturation cycles using yeast display resulted in the final development of a remarkable antibody able to recognize botulinum toxins A, B, E and F, the four serotypes afflicting humans 107, 108 .
Exploiting the recombinant nature of antibodies selected in vitro All in vitro selection systems immediately provide the genes and corresponding sequences of antibodies selected against a particular target. This provides ready access to additional antibody formats by simple subcloning. Functions adopted using this 'gene-based' approach include dimerization 109 , multimerization 110, 111 and fusions to enzymes 112 , tags 113 or fluorescent proteins 114 (Fig. 1) . Fusion to alkaline phosphatase is a particularly useful example of improved functionality. As this is a dimeric enzyme, fusing antibodies, either individually or as libraries, to alkaline phosphatase simultaneously provides dimerization and alkaline phosphatase activity, greatly facilitating screening by increasing the effective affinity and avoiding the need for secondary reagents 39, 112 . Short peptides acting as in vivo biotinylation tags 113 , placed at the C terminus of antibody fragments, allow stoichiometrically defined, site-specific antibody biotinylation, as well as straightforward multimerization 115 . Antibody fragments can also be transformed into full-length antibodies 116 , or scFv-Fc fusions, which are very similar in many aspects 117 . The use of engineered Fc regions can result in improved pharmacokinetics and effector functions (for reviews, see refs. 118, 119) , including bispecific IgG, in which engineering of two different Fc regions allows only heterologous pairing 120, 121 .
Other approaches to generate bispecific antibodies build upon the observation that some scFv fragments form bivalent dimers (diabodies) 122 , trimers 123, 124 and even tetramers 125 when the V H / V L linker is shortened. Additional bispecific antibody designs are reviewed elsewhere 126 . Even more radically, completely novel biochemical entities have been added to antigen-binding fragments. Fusions of scFv and Fab fragments to heterologous proteins, such as interleukins and cytokines 127, 128 , apoptotic ligands, enzymes, toxins or RNases (see refs. 129,130 for reviews) have allowed novel therapeutic paradigms. Many of the above candidate therapeutic antibody constructs arose from antibody genes initially isolated from mouse hybridomas, but this is expected to change as more human antibodies are made available from engineered repertoires.
Microinjected antibodies have long been used to knock out intracellular functions 131 . Antibody fragments can be expressed within target cells and targeted to various subcellular compartments 116, 132 by adding suitable signal sequences, allowing visualization or functional modification of proteins in different compartments. Removing the standard leader sequence results in cytoplasmic expression, whereas the addition of a nuclear localization signal results in antibodies being translocated to the nucleus. The combination of a leader sequence and the endoplasmic reticulum (ER) retention sequence retains expressed antibodies in the ER and has been used to prevent the expression of membrane proteins by sequestration in the ER. These include human interleukin 2 receptor, the ErbB2 receptor, β-amyloid precursor protein, vascular adhesion molecule 1 and many others [133] [134] [135] [136] . The advantage of this strategy is that it requires antibodies that bind to any accessible epitope to provide the functional knockout, as opposed to the functional activity required of cytoplasmically expressed antibodies. Functional studies of membrane receptors or secreted proteins can thus be attempted by a single standardized subcloning step immediately after in vitro antibody selection, providing equivalence to RNA interference knockdowns at the protein level.
Although expression in the secretory pathway is straightforward, folding of antibody fragments in the cytoplasm is far more challenging, owing to the reducing environment and the absence of specific chaperones, which prevents disulfide bond formation 137 . Despite these problems, there are examples where cytoplasmic proteins have been targeted with intracellular scFvs 78, 138 . The success of this approach has been improved by the creation of libraries of particularly stable scFvs [139] [140] [141] , preselecting antibodies for functional cytoplasmic expression 142, 143 , or by using binder libraries based on Figure 4 An engineered dual specificity synthetic Fab. The bH1 Fab binds to both Her2 (orange, Protein Data Bank (PDB) ID: 3BDY) and VEGF (red, PDB ID: 3BE1). The heavy and light chains of the Fab are colored cyan/gray or blue/black respectively, with the different colors derived from structures of bH1 binding to either Her2 or BEGF. p e r s p e c t i v e molecular scaffolds that do not rely on disulfide bond formation, such as engineered ankyrin repeat proteins 144, 145 . An important advantage of using such protein-based allosteric blockers is their ability to generate very specific binders capable of distinguishing between closely related family members. Although the need to genetically modify the target cell is a major disadvantage, this has been partly alleviated by fusion to internalizing sequences that allow antibodies to enter the cell from the outside 146 .
High-throughput selection by in vitro display methods
The ease with which antibodies can be selected, screened and produced by in vitro display technologies enables simpler and faster generation and screening of antibodies than with hybridomas. Typically, a panel of ELISA-positive monoclonal antibody fragments can be generated within 2 weeks. Early experiments demonstrated the feasibility of semi-automated selection and/or screening of phage antibody libraries [147] [148] [149] on small numbers of targets. More recently, selections on >400 different antigens were successful, with 54% of bacterially produced and 88% of mammalian-produced antigens 39 yielding antibodies. The differences between the two protein classes probably arise from differences in the levels of correct folding.
In a recent international comparative study, antibodies were raised to 20 different human Src-homology 2 (SH2) domains using hybridoma or phage display. Results from two of the participating phage display laboratories 60, 61 show that antibodies (some with subnanomolar affinities) were generated against all antigens, with 55% of positive antibodies specific for target SH2 domains when assessed against the entire SH2 panel. These antibodies were validated in a broad range of assays, including microarray analysis, immunoblotting, immunofluorescence and immunoprecipitation.
Prospects
If antibodies selected by in vitro methods are so powerful, why are they not more widely perceived as valuable research reagents? Part of the answer lies in the difficult patent situation, which resulted in restriction of this technology to the high-margin therapeutic markets for commercial use. It is worth noting in this regard that hybridoma technology was never patented, and achieved relatively wide acceptance within a short period. The situation for some of the core phagedisplay patents is now changing rapidly, as most platform patents have either expired or will do so over the next few years 150 . The technology may become more widely disseminated as a result.
Although largely unrecognized by the research community, it is worth emphasizing that some commercial 'monoclonal antibodies' are actually recombinant antibodies selected by phage display and then reformatted to look like traditional murine antibodies by the fusion of Fc regions to human variable regions (e.g., the sulfotyrosine antibody described above 45 ). Indeed, unmodified recombinant Fab fragments selected by phage display are commercially available. It therefore seems that the most important impediments to widespread adoption are a lack of knowledge of the capabilities of this technology, coupled with limited expertise and library availability. Furthermore, the number of companies willing to carry out in vitro selection for a fee is vanishingly small compared with the 180 companies willing to generate antibodies by immunization 16 .
Another explanation of why the strength of display technologies appears to be underappreciated relates to the difficulties encountered in expressing many of these antibodies. Although some of the specificities described above are remarkable, the expression and stability of antibody fragments varies enormously-from exceptionally stable scFv fragments used in clinical trials 151 to other fragments with extremely low expression levels. A typical selection almost always generates several different binders to any well-folded antigen. Among these, usually at least one is sufficiently stable and well produced for research use. Furthermore, it is expected that stability and expression levels will improve as libraries are based on more stable scaffolds 152 . The studies described above indicate that this goal can now be met in highly parallelized screening setups with low effort per antigen 60, 61 , provided that libraries of sufficient diversity and optimized protocols are used. Furthermore, stability and expression screening can be easily included as part of the high-throughput screening process. An additional issue with antibodies derived in vitro is that they are either not glycosylated if expressed in bacteria, or incorrectly glycosylated if expressed in standard yeast strains. If correct glycosylation is necessary, this can be overcome by expression in human cells or yeast modified to give human glycosylation patterns 153 .
Once an antibody is generated, it can be defined precisely by sequence and even 'distributed' in this way. Gene synthesis is progressing at a remarkable pace, with the cost-per-base of synthesized genes falling dramatically. In fact, genes corresponding to the sequences of specific antibody fragments can now be synthesized for less than the cost of purchase of some antibodies from traditional vendors.
The present state of this field can be compared to the situation for sequencing technologies at the start of the human genome project. Just as enormous technical advances occurred in the human genome project once it was started and rigorous industrial processes were applied, so we anticipate dramatic improvement in all aspects of selection, screening, downstream use and distribution of affinity reagents derived in vitro once a proteome-scale project is initiated and financed. In summary, in vitro display technologies permit the facile generation of antibodies by providing access to billions of potential binders in large 'universal' or immune display libraries. The technologies facilitate production, screening and maturation of selected binders, allowing selection on target conformations and formats not possible by more traditional routes based on immunization. Furthermore, the easy availability of the gene sequence not only provides a definitive description of the product but also allows electronic sharing and re-creation of the binding molecule through gene synthesis. The last 20 years have witnessed the successful application of display technologies to the development of therapeutic antibody candidates. In the coming decade we expect to also see increased realization of the benefits of this technology within the research and diagnostic markets.
